Hard to Treat Diseases, Inc.

Hard to Treat Diseases, Inc.

March 03, 2011 15:46 ET

Mellow Hope (HTDS) Seminar for Indian Medical Experts to Discuss Cerebroprotein Hydrolysate

SHENZEN, CHINA--(Marketwire - March 3, 2011) - Hard to Treat Diseases, Inc. (PINK SHEETS:HTDS) (www.htdsmedical.com) announced today that its China-based Shenzhen Mellow Hope subsidiary is planning a seminar for Indian medical experts.

The Indian experts are expected in China for the seminar and will visit Chinese medical experts in Beijing, Shanghai and Shenzhen. They will discuss plans to market 'Cognistar' (Cerebroprotein Hydrolysate for Injection) in India. Mellow Hope believes that this product will receive wide acceptance in the Indian market and has huge growth potential.

Mellow Hope finished the clinical trials of Cerebroprotein Hydrolysate for Injection in India. This biological product is a unique nutriment for the brain that helps the central nervous system in multiple ways, including: regulating and improving nerve cell metabolism; promoting synapse generation; inducing nerve cell differentiation; and protecting nerve cells against damages by ischemia and neurotoxins.

Mellow Hope looks forward to the visit from the Indian medical experts and plans to update investors as these developments progress.

Safe Harbor Statement

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

Contact Information